Trial Profile
THERAPEUTIC EFFICACY OF ABIRATERONE ACETATE VERSUS CONCOMITANT 177LU-DKFZ-PSMA-617 AND ABIRATERONE ACETATE THERAPY IN PATIENTS WITH METASTATIC CASTRATION RESISTANT PROSTATE CANCER: OPEN LABEL, TWO-ARM, PHASE II TRIAL
Status:
Not yet recruiting
Phase of Trial:
Phase II
Latest Information Update: 07 Jul 2022
Price :
$35
*
At a glance
- Drugs Lutetium (177Lu) vipivotide tetraxetan (Primary) ; Abiraterone acetate
- Indications Adenocarcinoma; Prostate cancer
- Focus Therapeutic Use
- 30 Jun 2022 Status changed from suspended to not yet recruiting, according to a Novartis media release.
- 30 Jun 2022 According to a Novartis media release, company has remediated the issues that led to the temporary, voluntary suspension. These issues did not affect patient safety, and no risk to patients from the doses previously produced at these sites was identified.Company restarted screening and enrollment for clinical trials with 177Lu-PSMA-617 (lutetium Lu 177 vipivotide tetraxetan) in the US, in most countries globally.
- 05 May 2022 According to Novartis media release, Novartis is putting a temporary hold on screening and enrollment for 177Lu-PSMA-617 clinical trials globally, hence status changed to suspended